ACP-211 vs BI 1569912
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
ACP-211
Developed by Acadia Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT07284667 (registry estimate)
No aligned efficacy figure on record for this race.
BI 1569912
Developed by Boehringer Ingelheim
NCT06280235 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 243 participants, using the clinical MADRS depression score as its primary endpoint. However, the prespecified primary dose-response analysis was not statistically significant, so the trial provides well-controlled but inconclusive evidence of benefit.
Reported efficacy
Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) (missed)
Result source: NCT06558344
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ACP-211 | BI 1569912 |
|---|---|---|
| MADRS, change (acute) | —Not reported | -12.3 vs -12−0.3 vs placeboNCT0628023510 other results
|
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | —Not reported | 34.8% vs 33.8%+1 vs placeboNCT062802355 other results
|
| MADRS remission | —Not reported | 21.2% vs 19.7%+1.5 vs placeboNCT062802352 other results
|
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- ACP-211
- —Not reported
- BI 1569912
- -12.3 vs -12−0.3 vs placeboNCT06280235
10 other results
- -10 vs -10.3 NCT06558344
- -19.9 vs -19.3 NCT04937829
- -11.9 vs -12 NCT06280235
- -10.6 vs -10.3 NCT06558344
- -7.8 vs -12 NCT06280235
- -13.6 vs -10.3 NCT06558344
- -16.8 vs -19.3 NCT04937829
- -5.7 vs -6.4 NCT06280235
- -5.9 vs -6.4 NCT06280235
- -5.2 vs -6.4 NCT06280235
CGI-S, change (acute)
- ACP-211
- —Not reported
- BI 1569912
- —Not reported
MADRS response
- ACP-211
- —Not reported
- BI 1569912
- 34.8% vs 33.8%+1 vs placeboNCT06280235
5 other results
- 15.5% vs 11.3% NCT06280235
- 31.4% vs 33.8% NCT06280235
- 11.1% vs 11.3% NCT06280235
- 20.6% vs 33.8% NCT06280235
- 11.1% vs 11.3% NCT06280235
MADRS remission
- ACP-211
- —Not reported
- BI 1569912
- 21.2% vs 19.7%+1.5 vs placeboNCT06280235
2 other results
- 25.7% vs 19.7% NCT06280235
- 8.8% vs 19.7% NCT06280235
Relapse (% of patients)
- ACP-211
- —Not reported
- BI 1569912
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ACP-211: no structured comparison results are available for Major Depressive Disorder.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ACP-211: 0 of 4 rows · BI 1569912: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | BI 1569912 |
|---|---|
| Dropout rate | 9.6%20 mga NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results7.3%10 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 12.5%5 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 9.6%20 mg NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 14.6%10 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 17.1%5 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5%20 mg NCT04937829 · Phase 1 15%5 mg NCT04937829 · Phase 1 |
| Discontinued due to AEs | 2.4%20 mga NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results4.9%10 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5%5 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 2.7%20 mg NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 4.9%10 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%5 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 —20 mg NCT04937829 · Phase 1 —5 mg NCT04937829 · Phase 1 |
| Serious AEs | 1.2%20 mga NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results2.4%10 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%5 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%20 mg NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 2.4%10 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%5 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%20 mg NCT04937829 · Phase 1 0%5 mg NCT04937829 · Phase 1 |
| Most frequent reported AEs | 20 mga dizziness 8.4% (placebo 2.5%) headache 8.4% (placebo 6.3%) nasopharyngitis 4.8% (placebo 3.8%) NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results10 mg headache 4.9% (placebo 6.3%) upper respiratory tract infection 2.4% (placebo 6.3%) dizziness 0% (placebo 2.5%) NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5 mg headache 7.5% (placebo 6.3%) nasopharyngitis 7.5% (placebo 3.8%) upper respiratory tract infection 5% (placebo 6.3%) NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 20 mg headache 12.3% (placebo 7.9%) nasopharyngitis 8.2% (placebo 3.9%) diarrhoea 2.7% (placebo 1.3%) NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 10 mg headache 9.8% (placebo 7.9%) diarrhoea 4.9% (placebo 1.3%) nasopharyngitis 4.9% (placebo 3.9%) NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5 mg headache 14.3% (placebo 7.9%) diarrhoea 5.7% (placebo 1.3%) upper respiratory tract infection 5.7% (placebo 1.3%) NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 20 mg decreased appetite 5% (placebo 5.3%) blood pressure increased 0% (placebo 0%) constipation 0% (placebo 0%) NCT04937829 · Phase 1 5 mg blood pressure increased 10% (placebo 0%) constipation 10% (placebo 0%) headache 5% (placebo 5.3%) NCT04937829 · Phase 1 |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
BI 1569912
show 10 more results
show 5 more results
show 2 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACP-211's landscape · BI 1569912's landscape